From concerning statistics on global health outcomes to new insights on AI and RWD, explore the top pharma news from July ...

CHENNAI: Gilead Sciences has achieved another milestone in its efforts to bring in a preventive drug to curb the still ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and low-resource settings, marking a major step in fighting global HIV spread.

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for ...

Rahway, New Jersey Wednesday, July 16, 2025, 17:30 Hrs [IST] ...

It has played an important role in testing for and tracking HIV infections. HIV/AIDS has no cure, and it has killed over 40 million people globally over the years.

The country isn’t getting extra money from the Global Fund to Fight Aids, TB and Malaria; it has to use cash from a grant it ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, ...

“According to UNAIDS, 1.3 million people acquired HIV in 2023, highlighting the continued need for new PrEP options like our investigational once-monthly, oral PrEP candidate MK-8527, especially ...

And now the number of HIV infections will grow. Medication is more difficult to obtain. At least 8,000 health workers in South Africa’s HIV program have already been laid off, the government has ...